Mata-Marín José Antonio, Mata-Marín Luis Alberto, Arroyo-Anduiza Carla Ileana, Huerta-García Gloria, Sandoval-Ramirez J L, Manjarrez-Tellez Bulmaro, Gaytán-Martínez J E
Hepatogastroenterology. 2014 Jul-Aug;61(133):1187-91.
BACKGROUND/AIMS: The most common HBV genotypes in HIV-coinfected patients in Mexico are H and G; the response to treatment for these genotypes is unknown. The aim of the study was to examine the effectiveness of intensification with pegylated interferon (PEG-IFN) alfa-2a or alfa-2b in HBV/HIV-coinfected patients treated with a tenofovir/emtricitabine (TDF/FTC) backbone in an HIV clinic in Mexico City.
We performed a single-arm open-label trial involving HBV/HIV-coinfected patients. Patients with chronic hepatitis B who were HBeAg positive were treated with TDF/FTC-containing regimen. Treatment was intensified by addition of PEG-IFN alfa-2b or alfa-2a for 24 weeks. The primary endpoint of effectiveness, assessed after 24 weeks, was suppression of HBV DNA to <60 IU/mL.
We enrolled 29 patients; 27 (93%) were men. HBV genotypes were F in 2 (6.9%), A in 2 (6.9%), G in 10 (34.5%), and H in 15 (51.7%). The primary endpoint was present in 17 (58%) patients (95% CI 29.7%–70.8%).
Intensification with PEG-IFN alfa-2a or alfa-2b is effective and well tolerated in patients with chronic hepatitis B who are HBeAg positive, have genotype H or G, and are coinfected with HIV while they are being treated with TDF/FTC-containing regimen.
背景/目的：在墨西哥，合并感染HIV的患者中最常见的HBV基因型是H型和G型；针对这些基因型的治疗反应尚不清楚。本研究的目的是在墨西哥城一家HIV诊所中，检验用聚乙二醇化干扰素（PEG-IFN）α-2a或α-2b强化治疗对接受替诺福韦/恩曲他滨（TDF/FTC）基础治疗的HBV/HIV合并感染患者的有效性。
我们开展了一项涉及HBV/HIV合并感染患者的单臂开放标签试验。HBeAg阳性的慢性乙型肝炎患者接受含TDF/FTC的治疗方案。通过加用PEG-IFNα-2b或α-2a强化治疗24周。24周后评估有效性的主要终点是将HBV DNA抑制至<60 IU/mL。
我们纳入了29例患者；27例（93%）为男性。HBV基因型为F型的有2例（6.9%），A型的有2例（6.9%），G型的有10例（34.5%），H型的有15例（51.7%）。17例（58%）患者达到主要终点（95%CI 29.7%–70.8%）。
对于HBeAg阳性、基因型为H型或G型、合并感染HIV且正在接受含TDF/FTC治疗方案的慢性乙型肝炎患者，用PEG-IFNα-2a或α-2b强化治疗有效且耐受性良好。
